>
High-Level Sources: Covert War In US, Israeli & Foreign Intel Agencies, Behind Epstein Case...
Hegseth Hosts Netanyahu at the Pentagon, Says It Was an 'Honor' To Be Part of the War Agains
Saagar Enjeti on the Dangerous New Developments in Pam Bondi's Epstein Cover-Up
Does Elon Musk's Third Party Have a Prayer? Trump Is Not a Believer
Insulator Becomes Conducting Semiconductor And Could Make Superelastic Silicone Solar Panels
Slate Truck's Under $20,000 Price Tag Just Became A Political Casualty
Wisdom Teeth Contain Unique Stem Cell That Can Form Cartilage, Neurons, and Heart Tissue
Hay fever breakthrough: 'Molecular shield' blocks allergy trigger at the site
High-Level Sources: Covert War In US,
Tesla Starting Integration of XAI Grok With Cars in Week or So
Bifacial Solar Panels: Everything You NEED to Know Before You Buy
INVASION of the TOXIC FOOD DYES:
Let's Test a Mr Robot Attack on the New Thunderbird for Mobile
Facial Recognition - Another Expanding Wolf in Sheep's Clothing Technology
Every year, 4,500 Americans die waiting for a kidney transplant. It's not just because there aren't enough donors—part of the problem is that donors need to be compatible to prevent the recipient's body from rejecting the new kidney. They need the right blood type, but they also have to have the right combination of six antigens--molecules on a cell that have the capacity to trigger an immune response. Any two random people have a one in 100,000 chance that all six antigens will match, and even then it's not a guarantee that the kidney won't be rejected.
Fifteen years ago, researchers from the Johns Hopkins University School of Medicine started developing a technique to quiet the recipient's immune system, making even incompatible donors a match. Now, after an eight-year study and evaluating thousands of patients, they have proof that this immune-quieting method works better than the alternatives and is saving lives, which could make it more widespread. The researchers published a study today in the New England Journal of Medicine.